Evidence map›Paper›PMID 24457987›Full record

ReviewCancer gene therapy2014

Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform.

J Wu, S Liu, J Yu, G Zhou, D Rao, C M Jay, P Kumar, R Sanchez, N Templeton, N Senzer and 3 more

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Cancer gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Pancreatic cancer actionable genes in precision medicine and personalized surgery.The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland · 2017
    Review
  9. Article
  10. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2016
    Article
  11. PDX1 associated therapy in translational medicine.Annals of translational medicine · 2016
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

J WuDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID 0000000150907573
S LiuDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
J YuDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
G ZhouDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
D RaoGradalis, Carrollton, TX, USA.
C M JayGradalis, Carrollton, TX, USA.
P KumarGradalis, Carrollton, TX, USA.
R SanchezDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
N TempletonGradalis, Carrollton, TX, USA.
N Senzer1] Gradalis, Carrollton, TX, USA [2] Mary Crowley Cancer Research Center, Dallas, TX, USA.
P MaplesGradalis, Carrollton, TX, USA.
J Nemunaitis1] Gradalis, Carrollton, TX, USA [2] Mary Crowley Cancer Research Center, Dallas, TX, USA.
F C BrunicardiDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
University of California, Los Angeles · USGradalis (United States) · USMary Crowley Cancer Research Center · US

Funding

PDX-1 is a Therapeutic Target for Pancreatic CancerR01CA095731 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BRUNICARDI, FRANCIS CHARLES · 2002 to 2012
$2.6M
NCI NIH HHS R01 CA95731
6 · The paper itself

Abstract

RNA interference (RNAi) represents a powerful, new tool for scientific investigation as well as a promising new form of targeted gene therapy, with applications currently in clinical trials. Bifunctional short hairpin RNA (shRNA) are synthetic RNAi molecules, engineered to utilize multiple endogenous RNAi pathways to specifically silence target genes. Pancreatic and duodenal homeobox 1 (PDX1) is a key regulator of pancreatic development, β-cell differentiation, normal β-cell function and pancreatic cancer. Our aim is to review the process of identifying PDX1 as a specific, potential RNAi target in pancreatic cancer, as well as the underlying mechanisms and various forms of RNAi, with subsequent testing and development of PDX1-targeted bifunctional shRNA therapy.

Indexed as

RNA InterferenceAnimalsCell LineClinical Trials as TopicGene TargetingGenetic TherapyHomeodomain ProteinsHumansMiceModels, BiologicalPancreatic NeoplasmsRNA, Small InterferingSwineSwine, MiniatureTrans-ActivatorsHomeodomain Proteinspancreatic and duodenal homeobox 1 proteinRNA, Small InterferingTrans-Activators

Identifiers

PMID24457987
OpenAlexW2017704180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.